Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1

Clinical Infectious Diseases

Volumn 41, Issue 2, 2005, Pages 227-232

  De Mendoza, Carmen ^a   Rodriguez, Carmen ^b   Eiros, José Maria ^c   Colomina, Javier ^d   Garcia, Federico ^e   Leiva, Pilar ^f   Torre Cisneros, Julián ^g   Aguero, Jesús ^h   Pedreira, José ⁱ   Viciana, Isabel ^j   Corral, Angélica ^a   Del Romero, Jorge ^b   Ortiz De Lejarazu, Raúl ^c   Soriano, Vincent ^a,k  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b CENTRO SANITARIO SANDOVAL   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^d HOSPITAL DE LA RIBERA   (Spain)

^e HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

ⁱ HOSPITAL JUAN CANALEJO   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^k NONE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CORRELATION ANALYSIS; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEROCONVERSION; STATISTICAL SIGNIFICANCE; VIREMIA; VIRUS DETECTION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 21844477835     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/431203     Document Type: Article

References (47)

1. Hirsch M, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with HIV-1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37: 113-28.
2. Brenner B, Routy J, Petrella M, et al. Persistence and fitness of multidrug-resistant HIV-1 acquired in primary infection. J Virol 2002; 76: 1753-61.
3. Garcia-Lerma G, MacInnes H, Bennet D, Weinstock H, Heneine W. Transmitted HIV-1 carrying D67N or K219Q evolve rapidly to zidovudine resistance in vitro and show a high replicative fitness in the presence of zidovudine [abstract]. Antivir Ther 2003;8:589.
4. Little S, Holte S, Routy J, et al. Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-94.
5. Wensing A, Boucher C. Worldwide transmission of drug-resistant HIV. AIDS Rev 2003; 5:140-55.
6. Grant R, Hecht F, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288: 181-8.
7. Soriano V, Ledesma E. Second Spanish consensus on the use of drug resistance testing in clinical practice (Madrid, March 2000). The Spanish HIV Drug Resistance Panel. AIDS Rev 2000; 2:111-8.
8. The Euroguidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as a part of treatment management. AIDS 2001; 15:309-20.
9. Gómez-Cano M, Rubio A, Puig T, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998; 12: 1015-20.
10. Puig T, Pérez-Olmeda M, Rubio A, et al. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. AIDS 2000; 14:727-32.
11. Gallego O, Ruiz L, Vallejo A, et al. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS 2001; 15:1894-6.
12. Briones C, Pérez-Olmeda M, Rodriguez C, del Romero J, Hertogs K, Soriano V. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconvertors in Madrid. J Acquir Immune Defic Syndr 2001; 26:145-50.
13. Pérez-Olmeda M, Del Romero J, Rubio A, et al. Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors. J Med Virol 2001; 63:85-7.
14. Yeni P, Hammer S, Hirsch M, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004;292:251-65.
15. Department of Health and Human Services Panel. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. November 2004. Available at: http://www.aidsinfo.gov. Accessed 15 December 2004.
16. Quinn T, Wawer M, Sewankambo N, et al. Viral load and heterosexual transmission of HIV-1. Rakai Project Study Group. N Engl J Med 2000; 342:921-9.
17. Hue S, Clewley J, Cane P, Pillay D. HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy. AIDS 2004; 18:719-28.
18. Eron J, Murphy R, Peterson D, et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS 2000; 14:1601-10.
19. Arnaiz J, Mallolas J, Podzamczer D, et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 2003; 17:831-40.
20. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA 2001; 285: 1155-63.
21. Ayouba A, Tene G, Cunin P, et al. Low rate of mother to child transmission of HIV-1 after nevirapine intervention in a pilot study public health program in Yaounde, Cameroon. J Acquit Immune Defic Syndr 2003; 34:274-80.
22. Jamieson D, Sibailly T, Sadek R, et al. HIV-1 viral load and other risk factors for mother to child transmission of HIV-1 in breast-feeding population in Cote d'Ivoire. J Acquir Immune Defic Syndr 2003; 34: 430-6.
23. Porco T, Martin J, Page-Shafer K, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004; 18:81-8.
24. Erice A, Mayers D, Strike D, et al. Primary infection with zidovudine-resistant HIV-1. N Engl J Med 1993; 328:1163-5.
25. Wensing A, van de Vijver D, Asjo B, et al. Prevalence of transmitted drug resistance in Europe is largely influenced by the presence of non-B sequences: analysis of 1400 patients from 16 countries: the CATCH study. Antivir Ther 2003;8:S131.
26. Duwe S, Brunn M, Altmann D, et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy naïve patients of the German seroconverter study. J Acquir Immune Defic Syndr 2001; 26: 266-73.
27. UK collaborative group of monitoring the transmission of HIV drug resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001; 322:1087-8.
28. Harzic M, Pellegrin I, Deveau C, et al. Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment. AIDS 2002; 16:793-6.
29. Yerly S, Vora S, Rizzardi P, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15: 2287-92.
30. Balotta C, Facchi G, Violin M, et al. Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J Acquir Immune Defic Syndr 2001; 27:499-505.
31. De Mendoza C, del Romero J, Rodriguez C, Corral A, Soriano V. Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. AIDS 2002; 16:1830-2.
32. Carpenter C, Fischl M, Hammer S, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998; 280:78-86.
33. Carpenter C, Cooper D, Fischl M, et al. Antiretroviral therapy in adults: updated recommendation of the International AIDS Society-USA Panel. JAMA 2000; 283:381-90.
34. Lori F, Foli A, Maserati R, et al. Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell response. HIV Clin Trials 2002; 3:115-24.
35. Metzner K, Bonhoeffer S, Fischer M, et al. Emergence of minor populations of HIV-1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003; 188: 1433-43.
36. Teicher E, Casagrande T, Vittecoq D. Enhanced risk of HIV sexual transmission during structured treatment interruptions. Sex Transm Infect 2003; 79:74.
37. Hirschel B. Beware of drug holidays before HIV salvage therapy. N Engl J Med 2003; 349:827-8.
38. De Mendoza C, Martin-Carbonero L, Barreiro P, et al. Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clin Trials 2002; 3:304-9.
39. Schooley R, Ruane P, Myers R. Tenofovir DF in antiretroviral experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257-64.
40. Pilcher C, Eron J, Galvin S, Gay S, Cohen M. Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest 2004; 113:937-45.
41. Berta B, Toro C, Paxinos E, et al. Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. AIDS 2004; 18:1109-16.
42. Leynaert B, Downs A, de Vincenzi I. Heterosexual transmission of HIV: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol 1998; 148:88-96.
43. + index partner, in discordant couples, Rakai, Uganda [abstract 40]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:71.
44. Holmberg S, Palella F, Lichtenstein K, Havlir D. The case for earlier treatment of HIV infection. Clin Infect Dis 2004; 39:1699-704.
45. Elford J, Bolding G, Sherr L. High-risk sexual behaviour increases among London gay men between 1998 and 2001: what is the role of HIV optimism? AIDS 2002; 16:1537-44.
46. Erbelding E, Chung S, Kamb M, Irwin K, Rompalo A. New sexually transmitted diseases in HIV-infected patients: markers for ongoing HIV transmission behaviour. J Acquir Immune Defic Syndr 2003; 33:247-52.
47. McGowan, Shah S, Ganea C, et al. Risk behaviour for transmission of HIV among HIV-seropositive individuals in an urban setting. Clin Infect Dis 2004; 38:122-7.